High-Dose, Home-Ready A New Approach to Nitric Oxide Therapy

Mallinckrodt Hospital Products IP Limited has filed a patent covering methods for administering nitric oxide from high-concentration cylinders at controlled dosing rates – an approach that could make this specialised respiratory therapy safer, more practical and more accessible, particularly for home use.

The Problem

Nitric oxide (NO) is a powerful therapeutic gas used in clinical medicine to treat pulmonary hypertension – a condition in which the blood vessels supplying the lungs become abnormally narrowed, forcing the heart to work harder and potentially leading to heart failure. When inhaled, nitric oxide acts selectively on the blood vessels of the lungs, causing them to dilate and reducing the pressure burden on the heart. It is particularly important in newborns with persistent pulmonary hypertension and in adults with certain forms of right heart dysfunction.

The problem with current nitric oxide delivery systems is their design around low-concentration storage. Conventional systems use cylinders containing nitric oxide at concentrations of 800 parts per million (ppm) or less. Because NO is reactive and can combine with oxygen to form nitrogen dioxide – a toxic gas – low concentrations have traditionally been seen as safer for storage and transport. However, maintaining large quantities of low-concentration gas requires numerous heavy cylinders, frequent replacements and complex logistics. This makes nitric oxide therapy inconvenient and expensive, and almost impossible to deliver effectively outside a hospital setting.

The clinical need for home-based nitric oxide administration is real and growing. Patients with chronic pulmonary conditions who require ongoing inhaled nitric oxide therapy cannot easily be tethered to hospital-grade equipment indefinitely. Enabling ambulatory and home therapy requires a fundamentally different approach to how NO is stored, transported and delivered.

What This Invention Does

The invention covers methods of administering nitric oxide from cylinders containing NO at concentrations greater than 2,000 ppm – significantly higher than the conventional ceiling of 800 ppm. The key insight is that using higher-concentration cylinders requires less gas volume to deliver the same therapeutic dose, meaning fewer, smaller and lighter cylinders are needed.

The critical safety element is the dosing rate. The methods described ensure that even when drawing from a high-concentration source, the rate at which NO is delivered to the patient is kept at or below 166 micrograms per second. By controlling this parameter precisely, the system can safely administer therapeutic doses without exposing patients to dangerously high concentrations of nitric oxide or allowing the formation of toxic nitrogen dioxide at harmful levels.

The invention effectively decouples the storage concentration from the delivery concentration. A high-concentration cylinder provides a compact, efficient reservoir; the administration method then governs how that reservoir is drawn down in a way that is safe and clinically appropriate. The result is a system potentially suitable for ambulatory use or home administration, opening up new possibilities for patients who currently rely on hospital-based treatment.

Key Features

High-concentration NO cylinders. The methods use cylinders containing nitric oxide at concentrations exceeding 2,000 ppm, enabling far greater storage efficiency compared to conventional low-concentration systems.

Controlled dosing rate. A maximum dosing rate of 166 micrograms of NO per second is specified, ensuring patient safety by preventing the delivery of excessive concentrations even when drawing from a high-concentration source.

Home-use suitability. The compact storage and controlled delivery approach is designed with ambulatory and home-based administration in mind, addressing a significant unmet need for chronic pulmonary hypertension patients.

Pulmonary hypertension indication. The invention is directed at treating conditions characterised by elevated pulmonary arterial pressure, a serious and progressive cardiovascular-pulmonary condition with limited treatment options.

Respiratory and cardiovascular IPC coverage. The international patent classification spans both pulmonary (A61P 11/00) and cardiovascular hypertension (A61P 9/12) indications, reflecting the dual therapeutic relevance of inhaled NO.

Who Is Behind It?

Mallinckrodt Hospital Products IP Limited is part of the Mallinckrodt group, a speciality pharmaceutical company with a significant focus on hospital and critical care products. The company has a long history in inhaled nitric oxide therapy, commercialising products used in intensive care settings globally. The inventors named are Brahm Goldstein and Douglas Stuart Greene, both with expertise in nitric oxide pharmacology and delivery systems. This application is a divisional of an earlier filing (AU 2022241504), indicating an ongoing and iterative development programme in this therapeutic area.

Why It Matters

Pulmonary hypertension remains a serious and often life-limiting condition. For patients requiring inhaled nitric oxide as part of their ongoing management, the current hospital-centric delivery model creates real limitations on quality of life, independence and the duration over which therapy can practically be sustained.

If validated and commercialised, a high-concentration, controlled-delivery system could transform how inhaled NO therapy is delivered – moving it from the exclusive domain of intensive care units and specialist hospitals into the home setting. This would represent a meaningful advance for patients, potentially enabling longer-term therapy, reducing hospitalisation time, and improving outcomes for those with chronic pulmonary hypertension. The work also reflects the broader trend towards enabling complex medical therapies to be delivered safely in community and home environments – a shift that is increasingly important as populations age and healthcare systems face growing capacity pressures.

---

AU 2026201565 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.